Last Updated: September 28, 2026

Viiv Hlthcare Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for VIIV HLTHCARE

VIIV HLTHCARE has twenty-six approved drugs.

There are seventeen US patents protecting VIIV HLTHCARE drugs.

Summary for Viiv Hlthcare

US Patents:	17
Tradenames:	19
Ingredients:	17
NDAs:	26

Drugs and US Patents for Viiv Hlthcare

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-002	Jan 21, 2021		RX	Yes	Yes	11,389,447	⤷ Start Trial				⤷ Start Trial
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-002	Jan 21, 2021		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Viiv Hlthcare	TRIUMEQ	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET;ORAL	205551-001	Aug 22, 2014		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Viiv Hlthcare	EPIVIR	lamivudine	TABLET;ORAL	020564-003	Jun 24, 2002	AB	RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790-002	Jun 9, 2016		DISCN	Yes	No	9,242,986*PED	⤷ Start Trial			Y	⤷ Start Trial
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790-002	Jun 9, 2016		DISCN	Yes	No	8,129,385*PED	⤷ Start Trial			Y	⤷ Start Trial
Viiv Hlthcare	VOCABRIA	cabotegravir sodium	TABLET;ORAL	212887-001	Jan 21, 2021		RX	Yes	Yes	10,927,129	⤷ Start Trial	Y	Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Viiv Hlthcare

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	RETROVIR	zidovudine	TABLET;ORAL	020518-002	Oct 4, 1996	4,833,130	⤷ Start Trial
Viiv Hlthcare	RETROVIR	zidovudine	TABLET;ORAL	020518-002	Oct 4, 1996	4,724,232	⤷ Start Trial
Viiv Hlthcare	RETROVIR	zidovudine	INJECTABLE;INJECTION	019951-001	Feb 2, 1990	4,833,130	⤷ Start Trial
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999	6,177,101	⤷ Start Trial
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-002	Jan 21, 2021	8,080,551	⤷ Start Trial
Viiv Hlthcare	RETROVIR	zidovudine	CAPSULE;ORAL	019655-001	Mar 19, 1987	4,837,208	⤷ Start Trial
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-001	Jan 21, 2021	8,080,551	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for VIIV HLTHCARE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	150 mg and 300 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Tablets	150 mg and 300 mg	➤ Subscribe	2011-08-08
➤ Subscribe	Oral Solution	20 mg/ml	➤ Subscribe	2012-12-27
➤ Subscribe	Tablets	150 mg/300 mg	➤ Subscribe	2007-06-26
➤ Subscribe	Tablets	10 mg, 25 mg and 50 mg	➤ Subscribe	2017-08-14
➤ Subscribe	Tablets	300 mg/150 mg/300 mg	➤ Subscribe	2011-03-22
➤ Subscribe	Oral Solution	10 mg/mL	➤ Subscribe	2011-11-22
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2009-01-28
➤ Subscribe	Tablets	700 mg	➤ Subscribe	2012-01-18
➤ Subscribe	Tablets	600 mg/300 mg	➤ Subscribe	2007-09-27
➤ Subscribe	Tablets	600 mg/50 mg/300 mg	➤ Subscribe	2017-08-14

International Patents for Viiv Hlthcare Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Singapore	10201509476R	⤷ Start Trial
South Korea	101562943	⤷ Start Trial
Lithuania	3372281	⤷ Start Trial
New Zealand	585294	⤷ Start Trial
European Patent Office	3187226	⤷ Start Trial
Israel	271555	⤷ Start Trial
Montenegro	01617	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Viiv Hlthcare Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2465580	2021/013	Ireland	⤷ Start Trial	PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/20/1481 20201221
0434450	990028	Netherlands	⤷ Start Trial	PRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBAAR ESTER, IN HET BIJZONDER ABACAVIR SULFAAT; REGISTRATION NO/DATE: EU/1/99/112/001-002 19990708
1874117	14C0041	France	⤷ Start Trial	PRODUCT NAME: DOLUTEGRAVIR ET SES SELS OU SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES,NOTAMMENT LE DOLUTEGRAVIR SODIQUE.; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
2465580	PA2021512	Lithuania	⤷ Start Trial	PRODUCT NAME: KABOTEGRAVIRAS; REGISTRATION NO/DATE: EU/1/20/1481 20201217
2924034	LUC00114	Luxembourg	⤷ Start Trial	PRODUCT NAME: DORAVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI EN COMBINAISON AVEC LA LAMIVUDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI EN COMBINAISON AVEC DU TENOFOVIR OU UN DE SES ESTERS, EN PARTICULIER UN ESTER DE DISOPROXIL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER UN SEL DE FUMARATE; AUTHORISATION NUMBER AND DATE: EU/1/18/1333 20181126
1874117	2023C/545	Belgium	⤷ Start Trial	PRODUCT NAME: DOULUTEGRAVIR SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/13/892 20140121
2932970	332 50016-2018	Slovakia	⤷ Start Trial	PRODUCT NAME: DOLUTEGRAVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM/RILPIVIRIN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/18/1282/001 - EU/1/18/1282/002 20180518
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Viiv Hlthcare

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.